Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer

Peled, Nir; Palmer, Gary A.; Hirsch, Fred R.; Wynes, Murry W.; Ilouze, Maya; Varella‐Garcia, Marileila; Soussan‐Gutman, Lior; Otto, Geoff; Stephens, Philip J.; Ross, Jeffrey S.; Cronin, Maureen; Lipson, Doron; Miller, Vincent A.

doi:10.1097/jto.0b013e3182614ab5

Cited by 120 publications

(94 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, two of the six mismatched cases had abnormalities in intron 19 of the ALK gene (Table 3). One of these patients was recently reported as having a complete response to crizotinib over 18 months [20].…”

Section: Discussionmentioning

confidence: 99%

“…Case 4 showed a complete response to therapy [20], with progression-free survival of 18 months, whereas case 5 presented stable disease.The other positive cases (with IHC) died before we could obtain a final conclusion regarding their tissue status (retrospective study).…”

Section: Response To Crizotinib Therapymentioning

confidence: 99%

“…In all studies, FISH was considered the gold standard. Because our clinical experience has shown that patients who were positive with IHC and negative with FISH may also benefit from ALK-related therapy [20], we wished to investigate whether FISH is indeed the appropriate gold standard. In this study, we tested 51 patients consecutively for ALK rearrangement by FISH and IHC and further sequenced any discordant specimens by next-generation sequencing (NGS).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

Background. The U.S. Food and Drug Administration-approved method for detecting EML4-ALK rearrangement is fluorescence in situ hybridization (FISH); however, data supporting the use of immunohistochemistry (IHC) for that purpose are accumulating. Previous studies that compared FISH and IHC considered FISH the gold standard, but none compared data with the results of next-generation sequencing (NGS) analysis. Materials and Methods. We studied FISH and IHC (D5F3 antibody) systematically for EML4-ALK rearrangement in 51 lung adenocarcinoma patients, followed by NGS in case of discordance. Results. Of 51 patients, 4 were positive with FISH (7.8%), and 8 were positive with IHC (15.7%). Three were positive with both. NGS confirmed that four of the five patients who were

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Response To Crizotinib Therapymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…In patients who have failed traditional therapy, the finding of an actionable mutation on an NGS panel has been associated, in some cases, with dramatic responses [48][49][50][51][52][53][54] . The merit of such off-label use is evaluated at present on a case-by-case basis.…”

Section: Importance Of Molecular Testing To the Healthcare Systemmentioning

confidence: 99%

The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer

Joseph

Cankovic

Caughron³

et al. 2016

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

“…However, as of June 2015, the VENTANA ALK (D5F3) CDx IHC assay (Ventana Medical Systems, Inc.) has been additionally approved. False negative and discordant ALK FISH results have been reported [1,2]. Here, we report patients who received false positive results on ALK FISH, leading to delay of optimal systemic therapy.…”

Section: Introductionmentioning

confidence: 94%

Fishing for Precision in ALK-Rearranged Non-Small-Cell Lung Cancers

Le¹,

Peters²

2015

Oncology and cancer case reports

View full text Add to dashboard Cite

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer

Cited by 120 publications

References 7 publications

Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer

Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer

The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer

Fishing for Precision in ALK-Rearranged Non-Small-Cell Lung Cancers

Contact Info

Product

Resources

About